2017-05-17 10:22:18COP   - $47.06
-0.07 (-0.15%) , TJX - $74.58
0.82 (1.11%) … 10:2205/17/17 05/1710:22 05/17/1710:22 | On The Fly: Top five analyst upgradesCatch up on today's top five analyst upgrades with this list compiled by The Fly: 1. ConocoPhillips (COP) upgraded to Buy from Hold at Jefferies with analyst Jason Gammel saying the company's divestitures have repaired the balance sheet faster than expected. 2. TJX (TJX) upgraded to Overweight from Equal Weight at Morgan Stanley with analyst Kimberly Greensberger saying the pullback in shares following the first quarter comparable store sales miss and soft second quarter guidance creates a buying opportunity. 3. Wolverine World Wide (WWW) upgraded to Outperform from Neutral at Baird with analyst Jonathan Komp citing improving fundamentals, ongoing business initiatives, margin recovery, and an attractive risk/reward. Komp raised his price target to $30 from $29 on Wolverine World Wide shares. 4. Windstream (WIN) upgraded to Outperform from Underperform at Raymond James with analyst Frank Louthan saying the 52% selloff since August 5, 2016 appears overdone given an improved free cash flow outlook from recent acquisitions. 5. Clovis (CLVS) upgraded to Overweight from Neutral at JPMorgan with analyst Cory Kasimov saying the shares are down 35% over the last two months for "no clear fundamental reason." This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here. COP - $47.06
-0.07 (-0.15%) TJX - $74.58
0.82 (1.11%) WWW - $24.90
0.255 (1.03%) WIN - $4.34
-0.11 (-2.47%) CLVS - $49.56
1.05 (2.16%) | |
|---|
- $47.06
-0.07 (-0.15%) - 05/17/17
- JEFF
05/17/17
UPGRADETarget $59
JEFF
Buy ConocoPhillips upgraded to Buy from Hold at Jefferies Jefferies analyst Jason Gammel upgraded ConocoPhillips to Buy and raised his price target for the shares to $59 from $55. The company's divestitures have repaired the balance sheet faster than expected, Gammel tells investors in a research note. He believes ConocoPhillips is well positioned to generate free cash flow, even in a low oil price environment. - 04/17/17
- RHCO
WPX Energy has positive read through from ConocoPhillips deal, says SunTrust After ConocoPhillips (COP) announced the sale of San Juan Basin assets to HilCorp Energy Company for $3B, SunTrust analyst Neal Dingmann says WPX Energy (WPX) has a positive read through from the deal, based on its nearby San Juan assets. He estimates that those assets are worth between $2.27-$2.83 per share. He keeps a $24 price target and a Buy rating on the name. - 05/11/17
- BOFA
05/11/17
DOWNGRADEBOFA
Neutral ConocoPhillips downgraded to Neutral from Buy at BofA/Merrill - 05/11/17
- BOFA
05/11/17
DOWNGRADETarget $67
BOFA
Neutral ConocoPhillips downgraded to Neutral on lower oil outlook at BofA/Merrill As previously reported, BofA/Merrill upgraded ConocoPhillips to Neutral from Buy and trimmed its price target to $67 from $68. Analysts led by Doug Leggate said oil markets are taking longer to re-balanced than previously expected and the commodity team lowered its mid year peak in Brent oil prices to $60 from $70 and said ConocoPhillips' share price could "stagnate" if current oil prices persist. - $74.58
0.82 (1.11%) - 05/17/17
- BMOC
TJX reported 'solid' Q1 results, says BMO Capital BMO Capital analyst John Morris says that TJX reported "solid" Q1 results. The analyst notes that the company's Q2 guidance came in below expectations, but he says the company has a history of providing conservative guidance. He remains upbeat on the company's longer term earnings outlook and on the off-price sector. Morris keeps an $85 price target and an Outperform rating on the shares. - 05/17/17
- RHCO
TJX weakness creates buying opportunity, says SunTrust SunTrust analyst Pamela Quintiliano says that TJX's weaker than expected Q2 guidance is conservative. She thinks that the company's fundamentals are "intact," while its results so far this year are "encouraging." The analyst reiterates a Buy rating. - 05/17/17
05/17/17
UPGRADETarget $86
Overweight TJX upgraded to Overweight following pullback at Morgan Stanley As previously reported, Morgan Stanley upgraded TJX to Overweight from Equal Weight with an $86 price target. Analyst Kimberly Greensberger said the pullback in shares following the Q1 comp miss and soft Q2 guidance creates a buying opportunity. The analyst expected Q1 to be soft given difficult comps and notes management maintained full year comp and earnings guidance. He views Q2 guidance as conservative and expects an acceleration in 2H earnings growth. - 05/17/17
- COWN
05/17/17
NO CHANGETarget $80
COWN
Outperform TJX weakness a buying opportunity, says Cowen Cowen analyst Oliver Chen said despite weak Q2 results for TJX he continues to believe growth prospects ahead are sustainable and achievable. He said comps are being driven by traffic, large store base works, and merchandise/inventory agility. Chen believes the weakness is a buying opportunity for long-term investors and he reiterated his Outperform rating, though he lowered his price target to $80 from $85 on TJX shares. - $24.90
0.255 (1.03%) - 02/03/17
On The Fly: Top five analyst downgrades Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Apache (APA) downgraded to Underperform from Neutral at Macquarie with analyst Paul Grigel citing a significantly lower revision in crude natural gas prices. The analyst expects Apache to ramp natural gas production in the second half 2017 and into 2018, at a time when he expects a decline in natural gas prices, creating lower cash flow and pressure on estimates given Apache's unhedged position. 2. GoPro (GPRO) downgraded to Underperform from Market Perform at Raymond James and to Underperform from Neutral at Baird. 3. Ralph Lauren (RL) was downgraded to Underweight from Neutral at Piper Jaffray, to Outperform from Buy at CLSA, and to Neutral from Buy at UBS. 4. lululemon (LULU) and Wolverine World Wide (WWW) were downgraded to Sector Weight from Overweight at KeyBanc. 5. Altria Group (MO) downgraded to Hold from Buy at Berenberg. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here. - 05/17/17
- BARD
05/17/17
UPGRADEBARD
Outperform Wolverine World Wide upgraded to Outperform from Neutral at Baird - 05/17/17
- BARD
05/17/17
UPGRADETarget $30
BARD
Outperform Wolverine World Wide upgraded to Outperform at Baird As previously reported, Baird analyst Jonathan Komp upgraded Wolverine World wide to Outperform from Neutral citing improving fundamentals, ongoing business initiatives, margin recovery, and an attractive risk/reward. Komp raised his price target to $30 from $29 on Wolverine World Wide shares. - 02/03/17
- KEYB
02/03/17
DOWNGRADEKEYB
Sector Weight Wolverine World Wide downgraded to Sector Weight from Overweight at KeyBanc KeyBanc analyst Edward Yruma downgraded Wolverine World Wide to Sector Weight after assuming coverage of the name. The analyst views the current valuation as fair. - $4.34
-0.11 (-2.47%) - 03/22/17
- GSCO
03/22/17
DOWNGRADETarget $1.5
GSCO
Sell Frontier Communications downgraded to Sell from Neutral at Goldman Goldman Sachs analyst Brett Feldman downgraded Frontier Communications (FTR) to Sell and cut his price target for the shares to $1.50 from $3. Weakening fundamentals may cause Frontier to suspend its dividend after the Q1 payment, Feldman tells investors in a research note. He believes the company cannot both support its dividend and delever. The analyst this morning also reinstated Windstream (WIN) with a Sell rating and lowered his price target for Sell-rated CenturyLink (CTL) to $19 from $21. - 03/22/17
- GSCO
03/22/17
INITIATIONTarget $4.5
GSCO
Sell Windstream reinstated with a Sell at Goldman Goldman Sachs analyst Brett Feldman reinstated Windstream shares with a Sell rating and $4.50 price target. The company's dividend has among the weakest coverage in the sector, the analyst contends. He also expects revenue and adjusted free cash flow to decline. - 03/15/17
On The Fly: Top five analyst initiations Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Snap (SNAP) initiated with an Underweight at Cantor. 2. Pattern Energy (PEGI) initiated with a Neutral at Goldman. 3. Windstream (WIN) reinstated with a Neutral at JPMorgan. 4. ClearOne (CLRO) resumed with a Buy at B. Riley. 5. REV Group (REVG) initiated with an Outperform at BMO Capital. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here. - 05/17/17
- RAJA
05/17/17
UPGRADETarget $5.25
RAJA
Outperform Windstream upgraded to Outperform from Underperform at Raymond James Raymond James analyst Frank Louthan upgraded Windstream to Outperform from Underperform with a $5.25 price target. The analyst said the 52% selloff since August 5, 2016 appears overdone given an improved free cash flow outlook from recent acquisitions. - $49.56
1.05 (2.16%) - 05/17/17
- JPMS
05/17/17
UPGRADETarget $72
JPMS
Overweight Clovis upgraded to Overweight from Neutral at JPMorgan JPMorgan analyst Cory Kasimov upgraded Clovis Oncology (CLVS) to Overweight and raised his price target for the shares to $72 from $58. The stock closed yesterday up 2%, or $1.05, to $49.56. The shares are down 35% over the last two months for "no clear fundamental reason," Kasimov tells investors in a research note. The analyst is "increasingly comfortable" recommending Clovis ahead of its Phase 3 study evaluating Rubraca in maintenance ovarian cancer now that more PARP class data has emerged. He has not seen "convincing evidence" that there is a clear efficacy difference between Clovis' rucaparib, Tesaro's (TSRO) niraparib and AstraZeneca's (AZN) olaparib. - 04/20/17
- LEER
04/20/17
NO CHANGETarget $158
LEER
Market Perform Tesaro price target lowered to $158 from $186 at Leerink Leerink analyst Seamus Fernandez lowered his price target for Tesaro (TSRO) to $158 from $186 on valuation. The analyst notes that the company announced the availability and launch of Zejula as well as pricing of $14,750/month, a 7% premium to Clovis' (CLVS) Rubraca, but he estimates an average pricing of $10,350/month given the frequency of dose reductions. Fernandez reiterates a Market Perform rating on the shares pending the results of TOPACIO and ARIEL3. - 04/18/17
- FBCO
04/18/17
INITIATIONTarget $74
FBCO
Outperform Clovis assumed with an Outperform at Credit Suisse Target $74. - 04/07/17
- MSCO
04/07/17
NO CHANGEMSCO
Overweight Clovis weakness a buying opportunity, says Morgan Stanley Morgan Stanley analyst Andrew Berens said the selloff in Clovis shares due to ARIEL3 database concerns represents a buying opportunity. The analyst believes some investors are trying to compare trial timelines to NOVA and predict ARIEL3 results, which is being compounded by healthcare and tax reform concerns, and the lack of M&A in smid biotech. Beren said management reiterated its prior broad ARIEL3 timing guidance to him on a call this morning, with the next update expected on the Q1 call. He told investors the sell off is a buying opportunity and recommends owning Clovis into both ARIEL3 and other PARP catalysts. Beren rates Clvois an Overweight with a $183 price target. |